Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients

Bone Marrow Transplantation volume 35, pages 509–513 (2005)Cite this article

Summary:

Voriconazole, a new antifungal agent, is increasingly being used after HSCT. The hepatic cytochrome P450 isoenzyme 2C19 plays a significant role in voriconazole metabolism. As CYP2C19 exhibits significant genetic polymorphism, some patients metabolize voriconazole poorly resulting in increased plasma drug levels. The clinical significance of this is unknown, and the utility of monitoring voriconazole levels is unclear. Steady-state trough plasma voriconazole levels were obtained in 25 allogeneic HSCT recipients using an HPLC assay. Patients had drug levels checked once (n=13), twice (n=10), or ⩾3 times (n=2) 5–18 days (median 10) after starting voriconazole or dose modification. The 41 voriconazole levels were 0.2–6.8 μg/ml (median 1.6); 6 (15%) were <0.5 (possibly below the in vitro MIC90 for Aspergillus spp.). Voriconazole concentrations correlated with aspartate aminotranferase (AST) (r=0.5; P=0.0009) and alkaline phosphatase (r=0.34; P=0.03), but not with creatinine, bilirubin and alanine aminotransferase (ALT). Since liver dysfunction is common after HSCT, it was not possible to determine if elevated AST and alkaline phosphatase levels were the cause or the consequence of higher voriconazole levels. We conclude that trough voriconazole levels vary considerably between patients, and suggest monitoring levels in patients receiving voriconazole for confirmed fungal infections, and in those with elevated AST or alkaline phosphatase levels.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole vs amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415.

    Article  CAS  Google Scholar 

  2. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225–234.

    Article  CAS  Google Scholar 

  3. Johnson LB, Kaufman CA . Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630–637.

    Article  CAS  Google Scholar 

  4. Tan KKC, Brayshaw N, Oakes M . Investigation into the relationship between plasma voriconazole concentrations and liver function test abnormalities in therapeutic trials. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago) 2001 (Abstr. A18).

  5. Mehta J, Powles R, Horton C et al. The relationship between donor–recipient blood group incompatibility and serum bilirubin after allogeneic bone marrow transplantation from HLA-identical siblings. Bone Marrow Transplant 1995; 15: 853–858.

    CAS  Google Scholar 

  6. Purkins L, Wood N, Ghahramani P et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546–2553.

    Article  CAS  Google Scholar 

  7. Lutsar I, Roffey S, Troke P . Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003; 37: 728–732.

    Article  Google Scholar 

  8. Hariprasad SM, Mieler WF, Holz ER et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthal 2004; 122: 42–47.

    Article  CAS  Google Scholar 

  9. Pennick GJ, Clark M, Sutton DA, Rinaldi MG . Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother 2003; 47: 2348–2350.

    Article  CAS  Google Scholar 

  10. Boyd AE, Modi S, Howard SJ et al. Adverse reactions to voriconazole. Clin Infect Dis 2004; 39: 1241–1244.

    Article  Google Scholar 

  11. Andes D, Marchillo K, Stamstad T, Conklin R . In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicob Agents Chemother 2003; 47: 3165–3169.

    Article  CAS  Google Scholar 

  12. Pfaller MA, Messer SA, Hollis RJ, Jones RN . Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002; 46: 1032–1037.

    Article  CAS  Google Scholar 

  13. Trifilio S, Verma A, Mehta J . Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplant 2004; 33: 735–739.

    Article  CAS  Google Scholar 

  14. Marty FM, Cosimi LA, Baden LR . Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950–952.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by the Auxiliary Board of the Northwestern Memorial Foundation.

Author information

Authors and Affiliations

  1. Pharmacy Department, Northwestern Memorial Hospital, Chicago, IL, USA

    S Trifilio & J Pi

  2. Hematopoietic Stem Cell Transplant Program, Division of Hematology/Oncology, The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA

    S Trifilio, R Ortiz, A Verma & J Mehta

  3. Department of Pathology, Fungus Testing Laboratory, University of Texas Health Science Center, San Antonio, TX, USA

    G Pennick

  4. Division of Infectious Diseases, The Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

    V Stosor & T Zembower

Authors
  1. S Trifilio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Ortiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Pennick
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Verma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Pi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V Stosor
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T Zembower
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Mehta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trifilio, S., Ortiz, R., Pennick, G. et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 35, 509–513 (2005). https://doi.org/10.1038/sj.bmt.1704828

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704828

Keywords

This article is cited by

Search

Advanced search

Quick links